| 张金娜,张莉娜.血清蛋白因子水平与首发精神分裂症患者认知功能障碍和PANSS评分的相关性研究[J].浙江中西医结合杂志,2018,28(8): |
| 血清蛋白因子水平与首发精神分裂症患者认知功能障碍和PANSS评分的相关性研究 |
| Relationship between Serum Protein Factor and Cognitive Dysfunction and PANSS Score in Patients with First-episode Schizophrenia. |
| 投稿时间：2017-10-03 修订日期：2018-06-26 |
| DOI： |
| 中文关键词: 神经生长因子-β 白介素-1β 钙结合蛋白 精神分裂症 认知功能 |
| 英文关键词:Nerve growth factor-β Interleukin-1β Calcium binding protein：Schizophrenia Cognitive function |
| 基金项目: |
|
| 摘要点击次数: 1340 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要：目的： 研究神经生长因子-β（Nerve Growth Factor，NGF-β）、白介素-1β（Interleukin 1β，IL-1β）、钙结合蛋白（calcium binding protein，S100β）三种血清蛋白因子水平与以阳性症状和阴性症状为主的首发精神分裂症患者认知功能障碍和PANSS评分之间的相关性。方法： 选择2013年5月至2016年10月间在我院住院就诊的精神分裂症患者97例作为研究对象，其中52例以阳性症状为主作为阳性症状组，45例以阴性症状为主作为阴性症状组，招募同期45例健康人作为对照组。采用酶联免疫吸附法（enzyme linked immunosorbent assay, ELISA）对所有受试者血清中的NGF-β、IL-1β、S100β水平进行检测，并以认知功能成套测验共识版（MCCB）来评估认知功能，并分析NGF-β、IL-1β、S100β水平与PANSS评分、MCCB各项目评分之间的相关性。结果： 阴性症状组和阳性症状组NGF-β水平[(19.45±6.14)ng/mL,(21.11±6.75)ng/mL]低于对照组[(45.24±9.79)ng/mL]，IL-1β[(81.45±17.72)ng/L,(62.91±14.46) ng/L]、S100β水平[(135.87±36.15)ng/L,(125.14±29.68)ng/L]均高于对照组[(25.85±5.12)ng/L, (102.57±29.87)ng/L]，差异均有统计学意义（P＜0.05＝。阳性症状组的IL-1β水平低于阴性症状组，差异有统计学意义（P＜0.05＝。阳性症状组和阴性症状组的NAB、CF、BACS SC、WMS-Ⅲ SS、BVMT-R、HVLT-R等因子的评分低于对照组，TMT评分高于对照组，差异均有统计学意义（P＜0.05＝。阳性症状组中NGF-β与PANSS总分和一般症状评分均呈正相关性（r=0.391,0.454；P=0.018,0.013），IL-1β与一般症状评分呈正相关性（r=0.319；P=0.024）。阳性症状组NGF-β水平和IL-1β水平均与BVMT-R呈正相关性（r=0.531,0.440；P＜0.05＝。结论： 血清蛋白因子水平与首发精神分裂症患者的认知功能障碍存在一定的联系，精神分裂症患者的中枢神经功能可能已经发生退化和损伤。 |
| 英文摘要: |
| Abstract: Objective: To study the correlation between the levels of nerve growth factor(NGF-β), interleukin-1β (IL-1β), calcium binding protein (S100β) and cognitive dysfunction and PANSS score in patients with primary schizophrenia with positive and negative symptoms. Methods: A total of 97 patients with schizophrenia were selected as the study subjects from May 2013 to October 2016, 52 cases with positive symptoms as the positive symptoms group, and 45 cases of negative symptoms as the negative symptoms group, another 45-healthy people were enrolled as controls. The levels of NGF-β, IL-1β and S100β in the serum of all subjects were detected by enzyme linked immunosorbent assay (ELISA). The cognitive function was evaluated by MCCB, and the correlation between NGF-β, IL-1β, S100β level and PANSS score and MCCB score was analyzed. Results: The levels of NGF-βand in the negative symptom group [(19.45±6.14) ng/mL] and the positive symptom group [(21.11±6.75) ng/mL] were lower than that in the control group [(45.24±9.79 ng/mL), IL-1β [(81.45 ±17.72) ng/L, (62.91±14.46) ng/L], S100β level [(135.87±36.15) ng/L, (125.14 ±29.68) ng/L] were higher than those in the control group [(25.85±5.12)ng/L, (102.57±29.87)ng/L], the differences were statistically significant (P <0.05). The level of IL-1β in the positive symptom group was lower than that in the negative symptom group (P <0.05). The scores of NAB, CF, BACS SC, WMS-Ⅲ SS, BVMT-R, HVLT-R in the positive and negative symptom groups were lower than those in the control group, and the TMT score was higher than that of the control group, the differences were statistically significant (P <0.05). There was a positive correlation between NGF-β level and PANSS scores, general symptom scores (r = 0.391,0.454; P = 0.018, 0.013), IL-1β was positively correlated with general symptom score (r = 0.319; P = 0.024). The levels of NGF-β and IL-1β in positive group were positively correlated with BVMT-R (r = 0.531,0.440; P <0.05). Conclusion: Serum protein factor levels are associated with cognitive dysfunction in first-episode schizophrenic patients. The central nervous system function of schizophrenic patients may have been degraded and damaged. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
